Colorectal cancer prevention in Europe: Burden of disease and status of screening programs

Altobelli, Emma; Lattanzi, Amedeo; Paduano, Riccardo; Varassi, G.; Orio, Ferdinando di

doi:10.1016/j.ypmed.2014.02.010

Cited by 144 publications

(121 citation statements)

References 77 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Although the death rate has decreased for decades owing to the implementation of screening strategies along with the improvement of standard treatment,30 the occurrence of relapses as well as the unfavorable prognosis still influences the consequence of treating CRC.…”

Section: Hoxa11‐as Lncrna In Human Cancersmentioning

confidence: 99%

HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers

Zhou

Xie

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

The cancers are the leading cause of disease‐related deaths worldwide with a high risk of morbidity and mortality. Long noncoding RNAs (lncRNAs) play a critical role in a wide range of biological processes, including tumorigenesis. HOXA11‐AS (NCRNA00076), the antisense strands of HOXA11 gene, was initially revealed in a mouse embryonic cDNA library in 2009 and it was a fairly novel lncRNA. This review summarized the advanced research progression concerning the expression and role of HOXA11‐AS in different human malignancies. The expression of HOXA11‐AS is aberrantly altered in many cancers, either as a tumor suppressor or as a tumor accelerator. The different underlying mechanism of HOXA11‐AS in different cancers (including, nonsmall cell lung cancers, osteosarcoma, uveal melanoma, glioma, hepatocellular carcinoma, gastric cancer, breast cancer, cervical cancer, ovarian cancer, colorectal cancer, ovarian cancer, and glioblastoma) was also detailed. These findings lead us to conclude that HOXA11‐AS participate in the complex network of cancers and plays an important role in the tumorigenesis and progression. Functional HOXA11‐AS could be a promising biomarker for early detection as well as prognosis evaluation in cancer patients. Future HOXA11‐AS‐targeted intervention may become a valuable novel therapeutic tool, improving the clinical management of cancers.

show abstract

Section: Hoxa11‐as Lncrna In Human Cancersmentioning

confidence: 99%

HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers

Zhou

Xie

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…The majority of these neoplasms are endoluminal adenocarcinoma derived from the mucosa, and over 95% of CRC patients benefit from surgery or colonoscopic interventions for premalignant polyps with early diagnosis (2). Despite advances in diagnosis and treatment and dissemination of communitybased screening, colorectal cancer remains to be one of the main reasons of cancer-related deaths in the world (3).…”

Section: Introductionmentioning

confidence: 99%

An evaluation of treatment results of emergency versus elective surgery in colorectal cancer patients

Bayar

Yılmaz

Akıncı

et al. 2016

UCD

View full text Add to dashboard Cite

Objective: Colorectal cancer is still one of the most common causes of cancer related deaths in the world despite improvements in diagnosis and treatment modalities, and application of community-based screening methods. Symptoms of colorectal cancer are non-specific and usually manifest following local progression. A number of patients with advanced stage colorectal cancer present to emergency departments with obstruction as the first sign of disease without any previous symptoms. This presentation is an indication for emergency surgery that has a high rate of morbidity and mortality. In this study, we aimed to determine the factors associated with early diagnosis and survival by comparing postoperative results of colorectal cancer patients who underwent surgery under emergency or elective situation. Material and Methods:Files of colorectal patients treated between 2009-2013 were retrospectively analyzed. Data on patient age, gender, operation type, intraoperative results, length of hospital stay, co-morbidities, postoperative complications and pathological results were evaluated and compared.Results: There was no statistical difference between groups in terms of age, gender, and pathology results (p>0.05). The difference between groups in terms of postoperative length of hospital stay, presence of co-morbid diseases, pathological stage, and postoperative complications was statistically significant (p<0.05). Length of hospital stay, advanced stage on admission, complications such as surgical site infection, evisceration, and anastomosis leakage rates were higher in patients in the emergency surgery group. Conclusion:Risk groups should be determined in order to diagnose colorectal cancer patients at an early stage while they are still asymptomatic, and this information should be incorporated into effective screening programs. This approach will be beneficial to treatment outcomes, complication rates, length of hospital stay, and survival and treatment results. INTRODUCTIONColorectal cancer (CRC) is one of the most frequent cancers with more than one million people worldwide being diagnosed with CRC annually, which is the most common gastrointestinal tract cancer (1). The majority of these neoplasms are endoluminal adenocarcinoma derived from the mucosa, and over 95% of CRC patients benefit from surgery or colonoscopic interventions for premalignant polyps with early diagnosis (2). Despite advances in diagnosis and treatment and dissemination of communitybased screening, colorectal cancer remains to be one of the main reasons of cancer-related deaths in the world (3).

show abstract

“…This is supported by evidence that early diagnosis improves outcomes: patients presenting with early, Duke's A stage, disease have a 93.2 % chance of 5-year survival, whilst individuals presenting with advanced, Duke's C or D, disease have only 47.7 % and 6.6 % 5-year survivals, respectively [5]. Europe-wide guidance for bowel cancer screening recommends a faecal occult blood test (FOBt) between the ages of 50-74, followed by colonoscopy if FOBt is positive [6]. Screening programme vary across the UK; for example in Scotland, it is performed from 50 to 74 years of age with optional opt-in after 75 years.…”

Section: Introductionmentioning

confidence: 99%

Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort

Bond

Burkitt

Sawbridge

et al. 2016

JGLD

View full text Add to dashboard Cite

Background & Aims: Colorectal cancer screening programmes that target detection and excision of adenomatous colonic polyps have been shown to reduce colorectal cancer related mortality. Many screening programmes include an initial faecal occult blood test (FOBt) prior to colonoscopy. To refine the selection of patients for colonoscopy other faecal-based diagnostic tools have been proposed, including tumour M2-pyruvate kinase (tM2-PK). To determine whether tM2-PK quantification may have a role in diverse settings we have assessed the assay in a cohort of patients derived from both the England bowel cancer screening programme (BCSP) and symptomatic individuals presenting to secondary care. Method. Patients undergoing colonoscopy provided faecal samples prior to bowel preparation. Faecal tM2-PK concentrations were measured by ELISA. Sensitivity, specificity, positive predictive value, negative predictive value and ROC analyses were calculated. Results. Ninety-six patients returned faecal samples: 50 of these with adenomas and 7 with cancer. Median age was 68. Median faecal tM2-PK concentration was 3.8 U/mL for individuals without neoplastic findings at colonoscopy, 7.7 U/mL in those with adenomas and 24.4 U/mL in subjects with colorectal cancer (both, p=0.01). ROC analysis demonstrated an AUROC of 0.66 (sensitivity 72.4%, specificity 48.7%, positive predictive value 67.7%, negative predictive value 36.7%). Amongst BCSP patients with a prior positive FOBt faecal tM2-PK was more abundant (median 6.4 U/mL, p=0.03) and its diagnostic accuracy was greater (AUROC 0.82). Conclusion. Our findings confirm that faecal tM2-PK ELISA may have utility as an adjunct to FOBt in a screening context, but do not support its use in symptomatic patients. Abbreviations: BCSP: Bowel cancer screening programme; EMR: Endoscopic mucosal resection; FAP: Familial adenomatous polyposis; FOBt: Faecal occult blood testing; NHS: National Health Service; tM2-PK: tumour M2-pyruvate kinase.

show abstract

Colorectal cancer prevention in Europe: Burden of disease and status of screening programs

Cited by 144 publications

References 77 publications

HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers

HOXA11 antisense long noncoding RNA (HOXA11‐AS): A promising lncRNA in human cancers

An evaluation of treatment results of emergency versus elective surgery in colorectal cancer patients

Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort

Contact Info

Product

Resources

About